DUBLIN--(BUSINESS WIRE)--The "Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1).
The report reviews Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
The report reviews key players involved in Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects.
The report assesses Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
The report summarizes all the dormant and discontinued pipeline projects.
The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics.
Companies Mentioned
- Incyte Corp
- Inflection Biosciences Ltd
- Jasco Pharmaceuticals LLC
- Novartis AG
- Sanofi
- SARomics Biostructures AB
- Tolero Pharmaceuticals Inc
- Yakult Honsha Co Ltd
For more information about this report visit https://www.researchandmarkets.com/research/43jllm/serinethreonine?w=4
